Did You Know...
...that the video game, Pong, was invented by a guy who graduated at the bottom of his engineering class? Nolan Bushnell spent more time running the games at a local amusement park than he did on his studies at the University of Utah. His dreams of working for Disney's amusement empire were dashed when the company wouldn't hire him. Taking a boring job, Nolan daydreamed about electronic versions of popular games. He invented Pong, the first video game, and went on to found Atari Co.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128769 | Solubilized CoQ-10 The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel ca... | 05/24/2012 |
| 20120128770 | TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE The present invention relates to 1 or 2 C16-C18 acyl glycerol based compounds which are capable of activating G-protein coupled receptor 119 and thereby stimulate GLP-1 release. Compounds of the present invention are useful in the prophylaxis and/or treatment of metabol... | 05/24/2012 |
| 20120039999 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in ei... | 02/16/2012 |
| 20120034298 | Chewable Soft Capsule A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properti... | 02/09/2012 |
| 20120009255 | METHODS OF TREATING INFECTIOUS DISEASES The present invention provides methods of treating a human or other mammal infected with a parasitic microorganism by administering an effective amount in unit dosage form of a C8-C16-alpha, beta-unsaturated aliphatic aldehyde, such as trans-2-dode... | 01/12/2012 |
| 20110311619 | PHARMACEUTICAL FORMULATION OF NANONISED FENOFIBRATE The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof.... | 12/22/2011 |
| 20110300210 | CONTROLLED RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent foll... | 12/08/2011 |
| 20110300211 | SOFT-GELATIN CAPSULE FORMULATION The present invention provides a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which includes: a soft gelatin capsule shell including gelatin and sugar alcohol as a plasticizer, and a mixture including a 15-keto-prostaglandin compound and a pharm... | 12/08/2011 |
| 20110287094 | SPECIFIC TIME-DELAYED BURST PROFILE DELIVERY SYSTEM The invention provides a delivery device for the delayed release of an active agent in the gastrointestinal tract comprising a core, comprising an active agent; a first outer coating, comprising a relatively hydrophobic substantially water insoluble polymer having subst... | 11/24/2011 |
| 20110287093 | ORAL DOSAGE FORMS WITH THERAPEUTICALLY ACTIVE AGENTS IN CONTROLLED RELEASE CORES AND IMMEDIATE RELEASE GELATIN CAPSULE COATS The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.... | 11/24/2011 |
| 20110268794 | METHODS AND MATERIALS FOR DELIVERING BILE ACIDS This document relates to methods and materials for administering bile acid compounds to treat conditions associated with constipation. For example, formulations designed for the delayed-release of a bile acid compound (e.g., sodium chenodeoxycholate) to treat constipati... | 11/03/2011 |
| 20110268793 | KITS AND METHODS FOR NUTRITION SUPPLEMENTATION The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D<... | 11/03/2011 |
| 20110244037 | PHARMACEUTICAL COMPOSITION COMPRISING A BI-CYCLIC COMPOUND AND METHOD FOR STABILIZING THE BI-CYCLIC COMPOUND Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): comprising the step of: admixing the same with a polyol and/or a fatty acid ester other than glyceride and a ... | 10/06/2011 |
| 20110244035 | Dosage Forms Dosage forms comprising therapeutically active compounds are disclosed herein.... | 10/06/2011 |
| 20110244036 | PHARMACEUTICAL COMPOSITION COMPRISING A BI-CYCLIC COMPOUND AND METHOD FOR STABILIZING THE BI-CYCLIC COMPOUND Disclosed is a method for stabilizing a pharmaceutically active bi-cyclic compound of formula (I): comprising the step of: admixing the same with a polyol and/or a fatty acid ester other than glyceride and a ... | 10/06/2011 |
| 20110229564 | Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof The present invention relates provides pharmaceutical compositions comprising an amorphous carvedilol salt and one or more pharmaceutically acceptable excipients, wherein the amorphous carvedilol salt is formed in situ during the preparation of the pharmaceutical compos... | 09/22/2011 |
| 20110229563 | Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity A material comprising from 30 to 80% by weight of ursolic acid, from 2 to 25% by weight of oleanolic acid and from 1 to 68% by weight of triterpenoic acids other than ursolic acid or oleanolic acid, or derivatives of any of these acids, said percentages being based on t... | 09/22/2011 |
| 20110229565 | Drug Delivery Composition Comprising a Self-Assembled Gelator This invention discloses drug-delivery compositions, methods of making prodrugs, and methods of drug delivery using a self-assembled gelator. The backbone of the gelator can contain a drug or prodrug, such as acetaminophen or salicin. Additional drugs or agents can be e... | 09/22/2011 |
| 20110223246 | DOCOSAHEXAENOIC ACID BOUND IN PHOSPHOLIPIDS AND METHOD OF RECOVERING SAME FROM A NATURAL SOURCE Medicaments and therapeutic compositions contain (1) phospholipids having 4,7,10,13,16,19-docosahexaenoic acid covalently bound thereto and (2) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty aci... | 09/15/2011 |
| 20110217370 | SUBSTANCES FOR PROMOTING HEALTHY JOINT FUNCTION COMPRISING GLUCOSAMINE SULFATE, OMEGA-3 POLYUNSATURATED FATTY ACIDS OR DERIVATIVES THEREOF, AND UNDENATURED TYPE II COLLAGEN Medicaments and therapeutic compositions contain (1) at least one omega-3 polyunsaturated fatty acid, or at least one pharmaceutically acceptable omega-3 polyunsaturated fatty acid derivative or mixtures thereof, (2) glucosamine sulfate, and (3) undenatured Type II coll... | 09/08/2011 |
| 20110212170 | Formulation For Retinoid-Containing Soft Gelatin Capsules A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated nat... | 09/01/2011 |
| 20110206763 | RAPID-RELEASE ENCAPSULATION COMPOSITION A rapid-release encapsulation composition that includes a gelatin and a water-insoluble rapid-release agent is provided. In particular, a rapid-release encapsulation composition that includes a gelatin and an insoluble carbonate salt is provided.... | 08/25/2011 |
| 20110200669 | METHOD AND COMPOSITIONS OF CIVAMIDE TO TREAT DISEASE OF THE INTESTINES Compositions and a methods are described for treating disorders of the small and large bowel, such as Crohn's disease, ulcerative colitis and irritable bowel syndrome, without producing any treatment-related systemic side effects and with minimal or no abdominal discomf... | 08/18/2011 |
| 20110189091 | COLON LAVAGE SYSTEM The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.... | 08/04/2011 |
| 20110171297 | SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE The invention provides a sustained release composition that; (1). Is free of initially increased drug delivery that occurs (in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or... | 07/14/2011 |
| 20110171300 | DELTA 9 TETRAHYDROCANNABINOL DERIVATIVES A compound of formula (I) wherein R is selected from
| 07/14/2011 |
| 20110171299 | DOXYCYCLINE METAL COMPLEX IN A SOLID DOSAGE FORM The present invention is a solid dosage form of a doxycycline metal complex. The present invention also includes a process for making a doxycycline metal complex in a solid dosage form. The process comprises the steps of (i) providing an aqueous solution of doxycycline ... | 07/14/2011 |
| 20110171301 | F, G, H, I and K Crystal Forms of Imatinib Mesylate The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain pro... | 07/14/2011 |
| 20110159088 | ORAL PHARMACEUTICAL FOR BASED ON AT LEAST ONE ACTIVE PRINCIPLE WHOSE SOLUBILITY VARIES AS A FUNCTION OF THE GASTRIC pH CONDITIONS The field of the present invention is that of oral pharmaceutical forms of at least one active principle AP whose solubility varies greatly as a function of the gastric pH, and also treatments and administration methods relating thereto. Th... | 06/30/2011 |
| 20110135721 | PREPARATIONS WITH ROSEHIP EXTRACTS, AND METHOD OF PRODUCING ROSEHIP EXTRACTS Composition comprising an anti-inflammatory plant extract from rosehips together with a cartilage-protective substance, and a method of producing the rosehip extract.... | 06/09/2011 |
| 20110129529 | Probiotic products for pet applications An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically Pediococcus acidilactici and Saccharomyces boulardii. Such encaps... | 06/02/2011 |
| 20110129518 | Probiotic products for pet applications An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically Pediococcus acidilactici and Saccharomyces boulardii. Such encaps... | 06/02/2011 |
| 20110123611 | PEPTIDYL DIACYLGLYCERIDES Peptide and peptides that may be covalently linked to a lipid and methods of using such peptides and lipopeptides to prevent or treat disease are disclosed herein.... | 05/26/2011 |
| 20110123610 | EXTENDED RELEASE COMPOSITIONS CONTAINING TOLTERODINE AND PROCESS FOR PREPARING THE SAME The present invention is directed to an extended release pharmaceutical composition such as tablets and capsules, and in particular to a matrix tablet composition comprising a therapeutically effective quantity of Tolterodine or pharmaceutical acceptable salts thereof i... | 05/26/2011 |
| 20110117191 | MIXTURE OF SUBSTANCES ON THE BASIS OF A MIXTURE OF ESSENTIAL OILS AND USE The invention relates to a substance mixture on the basis of a mixture of essential oils, wherein the oil mixture contains juniper oil and turpentine oil, in particular turpentine oil of the duster pine type or substantially comprises them, and wherein the substance mix... | 05/19/2011 |
| 20110111020 | Microcapsules Having Multiple Shells and Method for the Preparation Thereof Single-core and multi-core microcapsules are provided, having multiple shells, at least one of which is formed of a complex coacervate of two components of shell materials. The complex coacervate may be the same or different for each shell. Also provided are methods for... | 05/12/2011 |
| 20110097398 | REDUCTION OF CROSS-LINKING GELATIN IN GELATIN CAPSULES The invention relates to compositions and methods for reducing cross-linking in the gelatin shell of gelatin capsules by incorporation of free amino acid into the capsule shell and by inclusion of an ester of carboxylic acid either into the capsule filling, and/or into ... | 04/28/2011 |
| 20110091539 | Micronized Tanaproget and Compositions Containing Same The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, and magnesium stearate; or can contain microcrys... | 04/21/2011 |
| 20110086094 | CAPSULE FOR THE PREVENTION OF CARDIOVASCULAR DISEASES The invention relates to a capsule for the prevention of cardiovascular diseases which comprises coated tablets of acetylsalicylic acid, coated tablets of simvastatin or pravastatin, and coated tablets of lisinopril, ramiphl or perindopril. The capsules are used for the... | 04/14/2011 |
| 20110064803 | NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2 The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in th... | 03/17/2011 |
